Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
JAMA Ophthalmology|June 22, 2013
Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115Hidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, et al.
Nippon Ganka Gakkai Zasshi|October 9, 2003
[Effects of ocular hypotensive agents on the circadian rhythm in intraocular pressure in rabbits as measured by telemetry]Takahiro Akaishi, Atsushi Shimazaki, Takeshi Matsugi, et al.
American Journal of Ophthalmology|July 9, 2013
Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertensionHidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|February 15, 2022
Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL StudyDavid L Wirta, Yasuaki Kuwayama, Fenghe Lu, et al.
Acta Ophthalmologica|May 10, 2016
Change in visual acuity and associated risk factors after trabeculectomy with adjunctive mitomycin CKenji Kashiwagi, Satoshi Kogure, Fumihiko Mabuchi, et al.
Pageof 5